Accessibility Menu
SOPHiA Genetics logo

SOPHiA Genetics(NASDAQ) SOPH

Market Cap$643.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-54%
5 Year-55%
1 Year+141%
1 Month+36%
$7.59
-1.56%
-0.12Today
After hours$7.68+$0.09 (+1.19%)
SOPHiA Genetics last closing stock price
MetricPriceDate
Last closeUSD 7.672026-08-10
SOPHiA Genetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+34.8%USD 5.692026-08-03
1 month+35.75%USD 5.652026-07-10
3 month+65.66%USD 4.632026-05-12
Year to date+64.24%USD 4.672025-12-31
1 year+141.19%USD 3.182025-08-08
3 year+149.84%USD 3.072023-08-11
5 year-54.56%USD 16.882021-08-11
Since inception-54.24%USD 16.762021-07-23

SOPHiA Genetics Financials at a Glance

Market Cap

$643.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$86.17M

Net Income (TTM)

-$80.88M

EPS (TTM)

-$1.15

P/E Ratio

-6.66

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$7.59

Volume

408,024.474

Open

$7.86

Previous Close

$7.67

Daily Range

$7.48 - $7.88

52-Week Range

$2.97 - $7.88

Estimated Earnings Date

Nov 3, 2026

SOPH News

No articles available.

SOPH: Motley Fool Moneyball Superscore

68

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SOPHiA Genetics

SOPHiA GENETICS S.A. is a pioneering company in the healthcare technology sector, specializing in data-driven medicine. The firm offers the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution that analyzes diverse datasets to provide actionable insights for hospitals, laboratories, and biopharmaceutical organizations worldwide.

Products and Services
  • SOPHiA DDM platform for data analysis and insights
  • Comprehensive support services for healthcare institutions
  • Integration with various diagnostic tools and datasets
Growth Outlook
  • Revenue of $21.7 million in Q4 2025, showing consistent demand
  • TTM gross profit margin of 67.3%, indicating strong operational efficiency
  • Increasing adoption of SaaS solutions in healthcare, driving future growth
Financial Highlights
  • Recent quarterly revenue of $21.7 million, reflecting stable performance
  • Cash and cash equivalents of $65.4 million as of Q1 2026, ensuring liquidity
  • Operating expenses of $32 million in Q1 2026, highlighting investment in growth
SOPHiA GENETICS S.A. operates at the intersection of healthcare and technology, providing innovative solutions that enhance diagnostic capabilities. The SOPHiA DDM platform is designed to streamline the analysis of complex datasets, making it a valuable tool for healthcare professionals. The company's focus on data-driven medicine positions it well within a rapidly evolving industry, where the demand for advanced analytics is on the rise. The growth outlook remains promising, with a notable increase in revenue and a strong gross profit margin. The financial position is bolstered by significant cash reserves, allowing for continued investment in research and development. As the healthcare sector increasingly embraces digital transformation, SOPHiA GENETICS S.A. is poised to capitalize on these trends, making it an intriguing option for potential investors.
AI Generated • Jul 24, 2026

Industry

Health Care Technology

Sector

Health Care

Employees

415

CEO

Jurgi Camblong, PhD, EMBA

Website

www.sophiagenetics.com

Headquarters

Rolle, VD 1180, CH

SOPH Financials

Key Financial Metrics (TTM)

Gross Margin

66.63%

Operating Margin

-85.01%

Net Income Margin

-93.86%

Return on Equity

-136.71%

Return on Capital

-64.38%

Return on Assets

-40.77%

Earnings Yield

-15.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$643.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

83.90M

Volume

408.02K

Avg. Volume

299.97K

Financials (TTM)

Gross Profit

$57.41M

Operating Income

-$73.25M

EBITDA

-$65.11M

Operating Cash Flow

-$41.60M

Capital Expenditure

-$4.03M

Free Cash Flow

-$45.63M

Cash & ST Invst.

$107.67M

Total Debt

$61.83M

SOPHiA Genetics Performance Analysis

SOPHiA Genetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 47,560,00017.6%
20232023-12-31USD 62,371,00031.1%
20242024-12-31USD 65,173,0004.5%
20252025-12-31USD 77,271,00018.6%
SOPHiA Genetics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-306.2%
Q42025-12-3111.5%
Q12026-03-31-0.1%
Q22026-06-307.5%
SOPHiA Genetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.3618.3%
20232023-12-31USD -1.22-10.6%
20242024-12-31USD -0.95-22.4%
20252025-12-31USD -1.1723.6%
SOPHiA Genetics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.1%
Q42025-12-316.7%
Q12026-03-313.6%
Q22026-06-30-11.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$23.31M

+27.2%

Gross Profit

$15.06M

+22.7%

Gross Margin

64.61%

N/A

Market Cap

$643.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.55M

N/A

Employees

415

N/A

Net Income

-$22.36M

+0.3%

EBITDA

-$17.75M

+5.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$107.67M

+13.5%

Total Debt

$61.83M

-3.1%

Accounts Receivable

$14.11M

+48.5%

Inventory

$7.08M

+13.9%

Long Term Debt

$59.11M

-3.6%

Short Term Debt

$2.72M

+9.5%

Return on Assets

-40.77%

N/A

Return on Invested Capital

-49.73%

N/A

Free Cash Flow

-$10.39M

-2.0%

Operating Cash Flow

-$7.69M

+6.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NRCNRC Health
$20.90+2.75%
LRMRLarimar Therapeutics, Inc.
$4.01-3.61%
SLPSimulations Plus, Inc.
$18.35+0.16%
ANROAlto Neuroscience, Inc.
$28.29-1.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About SOPH

What is the current price of SOPHiA Genetics?

SOPHiA Genetics is trading at $7.67 per share.

What is the 52-week range for SOPHiA Genetics?

Over the past 52 weeks, SOPHiA Genetics has traded between $2.97 and $7.88.

How much debt does SOPHiA Genetics have?

As of the most recent reporting period, SOPHiA Genetics reported total debt of $62.43M.

How much cash does SOPHiA Genetics have on hand?

SOPHiA Genetics reported $65.39M in cash and cash equivalents in its most recent financial results.

What is SOPHiA Genetics’s dividend yield?

SOPHiA Genetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services